GenprexGNPX
About: Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Employees: 25
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
209% more capital invested
Capital invested by funds: $79.7K [Q3] → $247K (+$167K) [Q4]
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
5% more funds holding
Funds holding: 21 [Q3] → 22 (+1) [Q4]
5.01% less ownership
Funds ownership: 8.44% [Q3] → 3.42% (-5.01%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for GNPX.
Financial journalist opinion
Based on 3 articles about GNPX published over the past 30 days









